Aktuellt
SENASTE
BB Biotech is trading at a share price of CHF 36.9 compared to a net asset value per share of CHF 40.5, reflecting an 8.8% discount (vs. avg. 3% discount LTM and 11.4% premium in the last five years). The current head of Investment Management, Dr. Daniel Koller, will retire from his position and deputy head, Dr. Christian Koch, will take over at the beginning of 2025.
LÄS MER
